ArticleThe Journal of international medical research2025
The value of myositis-specific autoantibodies in the diagnosis of idiopathic inflammatory myopathy and tumor risk prediction.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveTo investigate the value of myositis-specific autoantibodies in the diagnosis of idiopathic inflammatory myopathy and tumor risk prediction in patients with clinically suspected idiopathic inflammatory myopathy.MethodsThis retrospective study analyzed the myositis-specific autoantibodies and clinical characteristics of 357 patients with clinically suspected idiopathic inflammatory myopathy. Statistical analyses were conducted to assess the associations between myositis-specific autoantibodies and clinical symptoms.ResultsAmong the 357 patients with suspected idiopathic inflammatory myopathy, the co-occurrence rate of anti-synthetase and anti-Ro52 was 52.63%. Univariate analysis demonstrated significantly higher diagnostic rates of idiopathic inflammatory myopathy in patients positive for anti-synthetase and anti-Ro52 than in those who were seronegative. Patients who tested positive for anti-signal recognition particle exhibited distinct serological profiles and diagnostic outcomes compared with those who tested negative. Significant associations were observed between myositis-specific autoantibodies and tumor biomarkers. Multivariate logistic regression analysis identified serum creatinine and anti-synthetase antibody positivity as independent diagnostic predictors of idiopathic inflammatory myopathy.DiscussionAnti-synthetase antibodies were independently associated with idiopathic inflammatory myopathy. Co-positivity for anti-synthetase and anti-Ro52 was closely related to the diagnosis of idiopathic inflammatory myopathy. Myositis antibodies were significantly correlated with tumor biomarkers, highlighting their potential utility in early cancer screening. Elevated serum creatinine was also independently associated with idiopathic inflammatory myopathy, exhibiting diagnostic significance.ConclusionMyositis-specific autoantibodies have potential clinical value for early tumor screening and the diagnosis of idiopathic inflammatory myopathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.